The Huaan Securities Research Report pointed out that the amount of small nucleic acid carriers released by Lanxiao Technology can be expected, and there is plenty of room for domestic replacement of ultrapure water. Net profit attributable to owners of the parent company in the first three quarters was 647 million yuan, a year-on-year decrease of 0.78%; of these, net profit attributable to owners of the parent company in the third quarter was 226 million yuan, up 9.12% year on year and 5.24% month on month. The basic plate of the peptide carrier is stable, and the small nucleic acid carrier opens a second growth curve. AI infrastructure is expanding, and there is plenty of room for domestic replacement of ultrapure water. Relying on jet homogenization technology and production capacity with completely independent intellectual property rights, the company has successively completed certification for core customers in the fields of downstream semiconductors, nuclear power, panels, etc., and has achieved stable commercial supply, breaking the technology monopoly of overseas companies, and there is broad space for domestic replacement. Affected by exchange rate fluctuations, financial expenses increased significantly compared to the same period last year, and the company's profit forecast was lowered. Subsequently, the company actively explored the implementation of localized production capacity in the direction of overseas construction resins and life science, and the gradual release of small nucleic acid carriers and ultra-pure water homogenized resin to maintain the “buy” rating.

The Huaan Securities Research Report pointed out that the amount of small nucleic acid carriers released by Lanxiao Technology can be expected, and there is plenty of room for domestic replacement of ultrapure water. Net profit attributable to owners of the parent company in the first three quarters was 647 million yuan, a year-on-year decrease of 0.78%; of these, net profit attributable to owners of the parent company in the third quarter was 226 million yuan, up 9.12% year on year and 5.24% month on month. The basic plate of the peptide carrier is stable, and the small nucleic acid carrier opens a second growth curve. AI infrastructure is expanding, and there is plenty of room for domestic replacement of ultrapure water. Relying on jet homogenization technology and production capacity with completely independent intellectual property rights, the company has successively completed certification for core customers in the fields of downstream semiconductors, nuclear power, panels, etc., and has achieved stable commercial supply, breaking the technology monopoly of overseas companies, and there is broad space for domestic replacement. Affected by exchange rate fluctuations, financial expenses increased significantly compared to the same period last year, and the company's profit forecast was lowered. Subsequently, the company actively explored the implementation of localized production capacity in the direction of overseas construction resins and life science, and the gradual release of small nucleic acid carriers and ultra-pure water homogenized resin to maintain the “buy” rating.